Paul Pescatello

Advocate for biotech/biopharma research & development as Sr Counsel/Executive Director-CT Bioscience Growth Council, Chair-WeWorkForHealthCT

[Paul Pescatello @CTBio]

Amgen's FGFR2b-targeting cancer candidate boosts overall survival in phase 3 https://t.co/ajIY7xQCik

[Paul Pescatello @CTBio]

J&J @JNJInnovation ties early-stage lymphoma CAR-T to 100% response rate in 10 patients https://t.co/xaRnqKA3ko

[CBIA @CBIANews]

“We’ve got to tell the story about a difference that we’re making in people’s lives,” @GovNedLamont said during a visit to CBIA member @ViiVUS honoring the company’s growth and breakthroughs in HIV treatment. https://t.co/SRbwSweOmp

#research #innovation #Connecticut

[Paul Pescatello @CTBio]

ASCO: Pfizer, chasing full approval conversion for Braftovi combo, touts 'unprecedented' survival win https://t.co/xvYiBz3cMq

[Chris DiPentima @ChrisDipentima]

Well-deserved recognition for Branford-based @ViiVUS, honored by @GovNedLamont for its global efforts to end HIV/AIDS. ViiV's cutting-edge research is at the forefront in the battle to end HIV, helping create 17 medications used by thousands of people across the globe.

[CBIA @CBIANews]

“#Innovation isn’t just technology, robots, and hardware,” @ChrisDipentima tells @WTNH's @MikeCerulliCT and @thevoiceofct's Melissa Sheketoff on MADE Conversations about how businesses innovate in areas like employee #engagement and #workplace culture. https://t.co/IlKJuAlG76

[Paul Pescatello @CTBio]

Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline https://t.co/zSX06NImnV

[BioSpace @biospace]

The @US_FDA accepted @novonordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the drug in the fourth quarter of this year.

#FDA #GLP1 #wegovy #biospace
https://t.co/Y3YxKK4ADK

[Paul Pescatello @CTBio]

Health Rounds: @boehringerus drug delivers 'unprecedented' result in lung cancer study https://t.co/oJP0EASaeM

[Paul Pescatello @CTBio]

https://t.co/ZS8xlRC5jn

[Paul Pescatello @CTBio]

Medtronic sends Hugo robot in for FDA review with urologic study success https://t.co/Nk2lQqPJza

[Pfizer Inc. @pfizer]

🎙️Out now! The bonus episodes of Science Will Win Season 4 recorded at SXSW are live! Hear how digital tools are empowering patients & how teamwork is key in the fight to out do cancer. Tune in on your favorite podcast app! 🎧 https://t.co/MiPazNe2aR

[Paul Pescatello @CTBio]

Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases https://t.co/WbkKVlG8Pb

[Arvinas @ArvinasInc]

#NEWS:Arvinas Presents First-in-Human Data for Investigational Oral novel PROTAC LRRK2 Degrader Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation.

Read More: https://t.co/1Nnfy48WXT

[Pharmaceutical Market Europe @PMLiVEcom]

AstraZeneca’s Imfinzi regimen approved by FDA to treat bladder cancer https://t.co/gQcL5bNL51 #News #Regulatory #AstraZeneca

[Paul Pescatello @CTBio]

‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD https://t.co/Wge69jkKPo

[Paul Pescatello @CTBio]

FDA signs off on Sanofi's insulin biosimilar, the first for Novo Nordisk's rapid-acting NovoLog https://t.co/QDRPykT62k

[CBIA @CBIANews]

“We’ve really hit our stride over the last couple of years in terms of new companies being born out of academic labs, and otherwise getting funding and starting in Connecticut,” CBIA's @CTBio tells @HartfordBiz about #Connecticut’s #bioscience industry.
https://t.co/RP3ysFHEyF

[CBIA @CBIANews]

CBIA Bioscience Growth Council’s @CTBio joined patients, advocates, policymakers, and industry leaders to highlight #RareDiseaseDay2025—raising awareness about these life-changing conditions and the #research and #innovation underway to improve the lives of patients and families.

[Pharmaceutical Market Europe @PMLiVEcom]

GSK’s five-in-one meningococcal vaccine Penmenvy granted FDA approval https://t.co/FgNV2tYVdJ #News #Regulatory #FDA